Pinealon
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, the 'EDR' peptide) from Vladimir Khavinson's Russian bioregulator research program, studied for its proposed neuroprotective and cognitive effects. In preclinical models it is investigated for protecting neurons against oxidative stress and supporting memory and circadian regulation. It is a research compound, not an approved drug.
Researchers and self-experimenters interested in the Khavinson brain/pineal bioregulator class and cognitive-aging models.
Pinealon is a short synthetic tripeptide composed of L-glutamic acid, L-aspartic acid and L-arginine (Glu-Asp-Arg), developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of Khavinson's 'peptide bioregulator' family. The central hypothesis in this research program is that small peptides can enter cells and interact with DNA regulatory regions to modulate tissue-specific gene expression, though this proposed epigenetic mechanism remains debated and is not firmly established outside the originating group's work.
In cell-culture and rodent studies, EDR peptide has been reported to protect cortical neurons against oxidative and hypoxic stress at nanomolar concentrations and to reduce markers of apoptosis. Aged or brain-injured animal models treated with Pinealon have shown improved performance on learning and memory tasks in some reports, alongside possible effects on circadian and antioxidant systems. The bulk of supporting evidence is Russian-language preclinical work plus small observational reports, including a frequently cited series in patients recovering from brain injury.
Independent, large, placebo-controlled Western clinical trials are lacking, so efficacy in humans should be considered unproven. Pinealon is NOT FDA-approved for any use, is not a recognized dietary supplement ingredient, and is sold for research purposes only. Anyone considering it should do so under qualified physician guidance and understand that safety and long-term effects in humans are not well characterized.
Community research protocols use subcutaneous injection at roughly 1-2 mg once daily; a conservative start is 1 mg/day, titrating upward only within a short cycle. Human data are thin, so the low end is the sensible default.
Any reported subjective effects (sleep, mental clarity) are typically described over 1-3 weeks of a cycle rather than acutely.
Sometimes stacked with other Khavinson bioregulators such as Cortagen or Epitalon in the same class; often run standalone.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.